325% return in 5 years: This multibagger stock in focus after H2 FY2025 results
Stock market news: There are stocks that have given multibagger returns to their investors. One such stock is of small-cap pharma company, Sudarshan Pharma Industries Ltd. The company's share price is in focus today during the trading session. The reason for this is that the company has announced its March quarter and FY 2025 results on Friday. Multibagger Pharma Stock closed at Rs 26.66 on May 2 with a decline of 1.99 per cent. The stock opened flat today but surged to hit the intraday high of Rs 27.99 on the BSE.
Sudarshan Pharma Industries shares have given more than 325 per cent return in 5 years.
In the second half of FY 2025, i.e. October 2024 to March 2025 (H2FY25), net sales of Sudarshan Pharma Industries Limited increased by 19 per cent to Rs 277 crore as compared to the same period a year ago. Net profit increased by 43 per cent to Rs 7 crore. EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization) margin also saw a good increase in H2FY25.
For the full financial year 2024-25, the company's net sales grew by 9 per cent to Rs 505 crore, while net profit grew by 45 per cent to Rs 16 crore. The company's market cap is Rs 642 crore. The company's compound annual profit growth has been 37 per cent in the last 5 years. India's pharmaceutical industry was worth around $42 billion in the year 2021. It can reach around $66 billion by 2025, while it can grow to $120-130 billion by 2030. During the March 2025 quarter, the company's revenue from operations grew 16.6 per cent year-on-year to Rs 277.26 crore from Rs 237.74 crore in the March 2024 quarter.
Sudarshan Pharma Industries has reported a net profit of Rs 10.03 crore during the quarter ended March 31, 2025. This profit is about 52 per cent higher than the net profit of Rs 6.64 crore recorded during the quarter ended March 31, 2024.
The pharma company told its investors that SPIL is working on boosting its exports. Along with this, it is actively working to increase domestic sales of its manufactured medicines. Apart from this, the company aims to improve profit margins by reselling active pharmaceutical ingredients (APIs) in India. Let us tell you that Sudarshan Pharma Industries manufactures specialty chemicals and intermediates for pharma, agro chemicals, paints, adhesives and other industries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
29 minutes ago
- Hans India
India's hospitality sector expected to clock 8 pc growth in FY26: Report
India's hospitality sector is expected to post a revenue growth of 6-8 per cent in FY2026 on the high base recorded after three years of double-digit revenue expansion seen by the industry over FY2023 to FY2025, according to an ICRA report released on Monday. ICRA estimates pan-India premium hotel occupancy to hold at 72-74 per cent in FY2026, slightly higher than the 70-72 per cent levels witnessed in FY2024 and FY2025. The average room rates (ARRs) for premium hotels are projected to rise to Rs 8,200-8,500 in FY2026, after a healthy Rs 8,000-8,200 in FY2025 amid lagging supply additions and several hotels undergoing renovation, refurbishment, and upgradation. Jitin Makkar, Senior Vice President ICRA Limited, said: "After three years of strong demand, driven by favourable domestic leisure travel, demand from meetings, incentives, conferences and exhibitions (MICE), including weddings, and business travel, the growth in the Indian hospitality sector is forecast to normalise at 6-8 per cent year-on-year in FY2026." "While the terror attacks in April 2025 and consequent heightened uncertainties in North and West India in May 2025 had led to a surge in cancellation of travel/MICE, the impact has been largely temporary and localised. In recent weeks, there has been a healthy recovery in sentiments following the abatement of the conflict," he added. Foreign tourist arrivals (FTAs) to India are expected to remain muted in the next few months in the aftermath of the terror attacks, but are estimated to witness a gradual recovery thereafter. However, domestic tourism has been the prime demand driver so far and is likely to remain so in the near term, the report states. Factors like improvement in infrastructure and air connectivity, favourable demographics, and anticipated growth in large-scale MICE events, with the opening of multiple new convention centres in the last few years, among others, shall support the growth over the medium term, according to the report. ICRA's sample set, comprising 13 large hotel companies, is likely to report range-bound operating margins of 34-36 per cent for FY2026, despite a lower revenue growth. The margins will remain supported by factors like cost rationalisation measures and asset-light expansions in recent periods. However, within the sample, it is likely to be a mixed bag, depending on renovations and an increase in employee expenses amidst growing demand. De-leveraging of balance sheets has led to lower interest costs and is likely to support net margins, as well as improvement in credit metrics, the report observes. 'The demand uptick over recent years led to an increase in supply announcements and resumption of deferred projects in the past 24-30 months. However, supply growth is expected to lag demand over the next 12-18 months." "ICRA's premium room inventory database (12 key cities) across the country indicates a compound annual growth rate (CAGR) of 4.5-5 per cent in room inventory addition during FY2023-FY2026. A large part of the new supply is through management contracts and operating leases. Land availability issues currently constrain supply addition in the premium micro-markets in metros and larger cities. The addition to premium hotel supply in these areas is largely on account of rebranding or property degradation, and the greenfield projects are largely being initiated in the suburbs," Makkar added.
NDTV
38 minutes ago
- NDTV
Starlink Device May Cost Rs 33,000 In India, Monthly Plan Charges Likely At Rs 3,000
Quick Read Summary is AI generated, newsroom reviewed. Elon Musk's Starlink plans to start operations in India soon, offering a satellite dish for Rs 33,000 and a monthly unlimited data plan for Rs 3,000. A trial month is included. The service aims to enhance connectivity in remote areas. New Delhi: Elon Musk's satellite internet service Starlink is preparing to commence operations in India within the next two months after receiving its license last week, sources said. The company has finalised its pricing structure for the Indian market, setting the cost of the required satellite dish device at approximately Rs 33,000. The monthly unlimited data plan is expected to be priced at Rs 3,000. As part of its launch strategy, Starlink plans to offer a complimentary one-month trial period with each device purchase, allowing customers to test the service before committing to regular monthly payments. The satellite internet service is expected to significantly impact connectivity in India's remote and underserved areas, where traditional broadband infrastructure has been challenging to establish. Starlink's low Earth orbit satellite constellation promises to deliver high-speed internet access to locations previously unreachable by conventional terrestrial networks. The pricing structure appears consistent with Starlink's regional strategy, as the device costs align with those in neighbouring countries. In Bangladesh, the Starlink device is priced at Rs 33,000, while Bhutan maintains the same Rs 33,000 price point for the equipment. Industry experts suggest that Starlink's entry into the Indian market could intensify competition in the country's telecommunications sector and provide crucial connectivity solutions for rural areas, educational institutions, and businesses in remote locations. The company's imminent launch comes as India continues to push for digital inclusion and improved internet connectivity across its vast geographical expanse, particularly in areas where traditional internet service providers have struggled to establish reliable networks.
Business Standard
39 minutes ago
- Business Standard
EPL allots 2.20 lakh equity shares under ESOS
EPL has allotted 2,20,222 equity shares under ESOS on 09 June 2025. In view of the said allotment, the paid-up equity share capital of the Company stands increased from Rs. 63,91,36,662 divided into 31,95,68,331 Equity Shares (having face value of Rs. 2 each) to Rs. 63,95,77,106 divided into 31,97,88,553 Equity Shares (having face value of Rs. 2 each).
